| Steven M Olsen, DO | |
|
1825 Logan Ave, Occupational Health, Waterloo, IA 50703-1916 | |
| (319) 235-3885 | |
| (319) 235-3113 |
| Full Name | Steven M Olsen |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine |
| Location | 1825 Logan Ave, Waterloo, Iowa |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336100528 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0500X | Preventive Medicine - Preventive Medicine/occupational Environmental Medicine | 02968 (Iowa) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Steven M Olsen, DO 1825 Logan Ave, Occupational Health, Waterloo, IA 50703-1916 Ph: (319) 235-3885 | Steven M Olsen, DO 1825 Logan Ave, Occupational Health, Waterloo, IA 50703-1916 Ph: (319) 235-3885 |
News Archive
Researchers have found that people born with a rare abnormality of their chromosomes have a 2,700-fold increased risk of a rare childhood leukaemia. In this abnormality, two specific chromosomes are fused together but become prone to catastrophic shattering.
Researchers in Manchester are questioning the legal use of certain fungicides used on imported flowers and bulbs following evidence that they induce resistance to the drugs used to treat patients with Aspergillus fumigatus, a virulent of fungal disease.
Microcomputed tomography of teeth can detect demarcated radiolucencies below the enamel–dentin junction that are of noncarious origin, and can therefore be classified as possible developmental irregularities, show study results.
In this post in the Center for Global Development's "Global Health Policy" blog, Amanda Glassman, director of Global Health Policy and a research fellow at the center, reports on last week's USAID- and World Bank-sponsored debate on treatment as prevention, "where debaters were asked to support or oppose the proposition that countries should spend the majority of flat or declining HIV prevention budgets on 'treatment as prevention,' building off the results of the HPTN 052 study which found a relative reduction of 89 percent in the total number of HIV-1 transmissions resulting from the early initiation of antiretroviral therapy.
Celgene International SÃ rl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.
› Verified 1 days ago